Novastan: Uses, Dosage & Side Effects
A synthetic direct thrombin inhibitor used for the prevention and treatment of thrombosis in adults with heparin-induced thrombocytopenia type II (HIT)
Novastan (argatroban) is a prescription intravenous anticoagulant belonging to the class of direct thrombin inhibitors. It is indicated for the prevention and treatment of thromboembolic complications in adult patients with heparin-induced thrombocytopenia type II (HIT-II) and as an anticoagulant during percutaneous coronary intervention (PCI) in patients who have or are at risk for HIT. Unlike heparin, argatroban exerts its effect independently of antithrombin and directly inhibits both free and clot-bound thrombin. Novastan is administered exclusively as a continuous intravenous infusion in a monitored hospital setting, with dose titration guided by activated partial thromboplastin time (aPTT). Because argatroban is hepatically cleared with a short half-life (40-50 minutes), treatment offers a rapid onset and offset of anticoagulation, making it a first-line parenteral option for patients requiring alternative anticoagulation when heparin is contraindicated.
Quick Facts: Novastan
Key Takeaways
- Novastan (argatroban) is a synthetic, reversible direct thrombin inhibitor (DTI) derived from L-arginine. It does not require antithrombin to exert its anticoagulant effect and inhibits both circulating and clot-bound thrombin.
- The principal indication is anticoagulation in adults with heparin-induced thrombocytopenia type II (HIT-II), a serious immune-mediated complication of heparin therapy. Novastan is also used during percutaneous coronary intervention (PCI) in patients with HIT or at risk of HIT.
- Argatroban is administered only as a continuous intravenous infusion with an initial adult rate of 2 micrograms/kg/min, titrated to a target activated partial thromboplastin time (aPTT) of 1.5-3 times baseline (not exceeding 100 seconds).
- The half-life is short (40-50 minutes) in patients with normal hepatic function, giving rapid onset and offset. Dose reduction is mandatory in hepatic impairment, heart failure, post-cardiac surgery, and severe anasarca; no dose reduction is needed for renal impairment.
- Bleeding is the main safety concern. Argatroban also prolongs the international normalized ratio (INR), which must be accounted for during transition to warfarin using standardized overlap protocols. There is no specific reversal agent; management of bleeding relies on drug discontinuation and supportive measures.
What Is Novastan and What Is It Used For?
Novastan contains the active substance argatroban, a small-molecule synthetic anticoagulant derived from the amino acid L-arginine. Argatroban belongs to the pharmacological class known as direct thrombin inhibitors (DTIs), which act at the final step of the coagulation cascade to block the enzyme thrombin (coagulation factor IIa). Thrombin is the central mediator of haemostasis: it converts soluble fibrinogen into insoluble fibrin, activates platelets, and amplifies further thrombin generation by activating coagulation factors V, VIII and XI. By neutralising thrombin, argatroban interrupts all of these downstream events and rapidly establishes therapeutic anticoagulation.
Unlike unfractionated heparin (UFH) and low-molecular-weight heparins (LMWH), which exert their effect indirectly by enhancing the activity of antithrombin, argatroban binds directly and reversibly to the catalytic (active) site of thrombin. This antithrombin-independent mechanism is clinically important in situations where heparin is ineffective, unsafe, or contraindicated - most notably in heparin-induced thrombocytopenia type II (HIT-II), where continued exposure to heparin would trigger or worsen life-threatening thrombosis. Because the interaction with thrombin is reversible and non-covalent, the anticoagulant effect of argatroban dissipates within hours of stopping the infusion, which is a significant clinical advantage when rapid reversal of anticoagulation is required.
Argatroban is also capable of inhibiting clot-bound (fibrin-associated) thrombin, unlike heparin, which is sterically hindered from reaching thrombin trapped within an established thrombus. Clot-bound thrombin continues to drive clot propagation even when plasma thrombin has been neutralised; inhibiting this pool provides a more complete antithrombotic effect during active thrombosis. Argatroban does not inhibit platelet function directly and does not interact with heparin-platelet factor 4 (PF4) antibodies that underlie the pathophysiology of HIT, making it pharmacologically well-suited to managing patients with this condition.
The main approved indications for Novastan (argatroban) vary slightly between regulatory agencies but share a common core:
- Adult patients with heparin-induced thrombocytopenia type II (HIT-II): Argatroban is indicated for anticoagulation in adults with HIT-II who require parenteral antithrombotic therapy. This includes patients with established HIT-associated thrombosis as well as those with isolated HIT (thrombocytopenia without overt thrombosis) in whom continued anticoagulation is clinically warranted.
- Percutaneous coronary intervention (PCI): Argatroban is used as an anticoagulant during PCI (such as balloon angioplasty or coronary stent placement) in adult patients who have or are at risk of developing HIT. In this setting it provides a non-heparin alternative to support the procedure without triggering an immune reaction.
- Off-label and specialist use: Argatroban is used by specialist centres for anticoagulation during continuous renal replacement therapy (CRRT), extracorporeal membrane oxygenation (ECMO), and cardiopulmonary bypass in patients with HIT or acute heparin resistance, although formal approval for these indications varies by jurisdiction.
Argatroban was first approved for clinical use in Japan in 1990 and has since been approved in the United States (FDA, 2000) and the European Union (centralised EMA procedure, 2005, for the brand Argatra). Novastan is one of the original trade names under which argatroban has been marketed in Europe, the United Kingdom, and parts of Asia. The active ingredient is included on the World Health Organization's list of essential medicines for parenteral anticoagulation in HIT, reflecting its global clinical importance. Multiple generic argatroban formulations are now available, and the medication is considered a cornerstone therapy for HIT alongside other non-heparin anticoagulants such as danaparoid, bivalirudin, and fondaparinux.
Heparin-induced thrombocytopenia type II is a prothrombotic, immune-mediated drug reaction caused by antibodies to heparin-platelet factor 4 (PF4) complexes. Paradoxically, despite causing a drop in platelet count, HIT produces a hypercoagulable state with a 30-day thrombosis risk of up to 50% if untreated. Rapid substitution of heparin with a non-heparin anticoagulant such as Novastan is therefore life-saving.
What Should You Know Before Taking Novastan?
Contraindications
Novastan is contraindicated in the following situations:
- Active major bleeding: Any uncontrolled, clinically significant haemorrhage including gastrointestinal, intracranial, retroperitoneal, pulmonary, or surgical bleeding contraindicates the initiation of argatroban. The drug must be withheld until the source of bleeding is controlled.
- Severe hepatic impairment: Because argatroban is eliminated almost exclusively by hepatic metabolism, patients with severe hepatic impairment (Child-Pugh C or clinically severe cirrhosis) are at risk of excessive accumulation, unpredictable pharmacokinetics, and life-threatening bleeding. In most European labelling, severe hepatic impairment is an absolute contraindication; in the United States, argatroban carries a strong warning rather than a formal contraindication in this setting and should only be used with substantial dose reduction and close monitoring.
- Hypersensitivity: Known hypersensitivity to argatroban or any of the excipients in the formulation (including D-sorbitol and ethanol in certain formulations).
- Pregnancy and breastfeeding (precautionary): Formal contraindications vary by product information, but argatroban should be avoided during pregnancy and breastfeeding unless the benefits clearly outweigh potential risks. See the dedicated section on pregnancy below.
Warnings and Precautions
All anticoagulants, including argatroban, carry a risk of serious and potentially fatal bleeding. The most clinically important complications are intracranial haemorrhage, gastrointestinal bleeding, and retroperitoneal bleeding. Patients should be assessed for bleeding risk before initiation, monitored continuously during therapy, and evaluated for any change in neurological status, haemodynamics, or laboratory indices of anaemia. There is no specific antidote for argatroban; management of bleeding relies on discontinuation of the infusion and supportive measures.
Before starting Novastan, discuss the following with your healthcare provider:
- Hepatic (liver) disease: Because argatroban is cleared almost exclusively by the liver, hepatic impairment markedly prolongs its half-life and increases the risk of accumulation. In moderate hepatic impairment (Child-Pugh B), the initial dose should be reduced to 0.5 micrograms/kg/min. Liver function tests (bilirubin, AST, ALT, albumin, INR) should be obtained before therapy in any patient with suspected liver disease.
- Recent major surgery or trauma: Recent major surgery (including neurosurgery, ophthalmic surgery, and cardiac surgery), severe trauma, organ biopsy, or obstetric delivery within the previous 48-72 hours increases the risk of bleeding. The risks and benefits should be carefully weighed.
- Severe, uncontrolled hypertension: Uncontrolled blood pressure (systolic >180 mmHg or diastolic >110 mmHg) increases the risk of intracranial and retinal haemorrhage. Blood pressure should be optimised before starting argatroban where possible.
- Congenital or acquired bleeding disorders: Pre-existing haemophilia, von Willebrand disease, disseminated intravascular coagulation (DIC), thrombocytopenia unrelated to HIT, severe liver disease-associated coagulopathy, or uraemia-induced platelet dysfunction all heighten bleeding risk.
- Gastrointestinal ulceration and recent GI bleeding: Active peptic ulcer disease or a history of gastrointestinal haemorrhage increases the risk of clinically significant GI bleeding during argatroban therapy.
- Recent stroke or spinal procedures: Recent ischaemic stroke (within the past 2-4 weeks), recent lumbar puncture, spinal or epidural anaesthesia, or intrathecal procedures all increase the risk of intracranial, spinal, or epidural haematoma formation. Neurological monitoring is essential if these procedures cannot be avoided.
- Heart failure, post-cardiac surgery, and severe anasarca: These conditions impair hepatic perfusion, reducing argatroban clearance. Initial dose reduction (typically to 0.5-1.2 micrograms/kg/min) is recommended.
Laboratory Monitoring
Argatroban must not be used without appropriate laboratory monitoring. The standard assay for monitoring argatroban therapy is the activated partial thromboplastin time (aPTT). The target aPTT is 1.5 to 3 times the patient's baseline value, not exceeding 100 seconds. A baseline aPTT should be measured before starting the infusion; a repeat aPTT should be obtained approximately 2 hours after starting therapy and after every dose change; once stable, monitoring should continue at least daily (and more frequently in critical care or peri-procedural settings). In selected settings, chromogenic anti-IIa activity assays or dilute thrombin time (dTT) may be used as alternatives, particularly when the aPTT is elevated at baseline due to lupus anticoagulant, factor deficiencies, or concomitant coagulopathy.
Transition to Oral Anticoagulation (Warfarin)
Argatroban independently prolongs the international normalized ratio (INR), which makes it difficult to interpret warfarin therapy during overlap. Standardised transition protocols should be used:
- For argatroban doses up to 2 micrograms/kg/min, continue argatroban while starting warfarin. Measure the combined INR daily. Once the combined INR exceeds 4 on at least two consecutive measurements, stop argatroban and recheck the INR 4-6 hours later. If the warfarin-alone INR is within the therapeutic target (usually 2.0-3.0), discontinue argatroban permanently. If the INR is below target, resume argatroban and repeat the overlap procedure the following day.
- For argatroban doses exceeding 2 micrograms/kg/min, the dose should first be reduced to 2 micrograms/kg/min; the combined INR should then be remeasured 4-6 hours later and the protocol above applied.
Children and Adolescents
Limited data are available regarding the safety and efficacy of argatroban in children and adolescents, and paediatric HIT is rare. Specialist paediatric haematology guidance should be sought in any child or adolescent who may require argatroban therapy. Paediatric pharmacokinetic studies suggest that clearance is reduced and the half-life is prolonged in children under 16 years of age, particularly in critically ill children with impaired hepatic function; lower starting doses (often 0.75 micrograms/kg/min or less) are recommended in this population.
Pregnancy and Breastfeeding
The experience of argatroban use in pregnancy is limited to case reports and small case series, primarily in pregnant patients with HIT in whom heparin-based anticoagulants were contraindicated. Animal reproduction studies have not demonstrated direct teratogenic effects or impaired fertility. However, argatroban is a small molecule that may cross the placenta, and the potential effects on the foetus cannot be fully excluded. Argatroban should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the foetus, typically in the context of HIT with active thrombosis.
It is not known whether argatroban is excreted in human breast milk. Because of the theoretical risk of serious adverse reactions in the nursing infant and the unpredictable pharmacokinetics in neonates, breastfeeding is generally not recommended during argatroban therapy. The decision to discontinue breastfeeding or to discontinue argatroban should be individualised based on the clinical situation.
Driving and Operating Machinery
Argatroban is administered in a hospital setting to patients who are typically acutely unwell and under bed rest. Consequently, effects on the ability to drive or operate machinery are not relevant during active therapy. After discharge, once argatroban has been fully cleared, there are no residual effects on cognitive or motor function.
How Does Novastan Interact with Other Drugs?
The drug interactions of argatroban are primarily pharmacodynamic (additive effects on haemostasis) rather than pharmacokinetic. Because argatroban is a small molecule that is hepatically eliminated through hydroxylation and aromatization with only a limited contribution from cytochrome P450 enzymes, clinically important CYP-mediated interactions are uncommon. However, any medication that alters platelet function or coagulation can additively increase the risk of bleeding when co-administered with argatroban.
Major Interactions
The following combinations require dose adjustment, enhanced monitoring, or careful risk-benefit assessment:
| Drug / Class | Mechanism | Clinical Management |
|---|---|---|
| Warfarin | Additive prolongation of INR; both affect the prothrombin time pathway | Use standardised overlap protocol; stop argatroban once warfarin-alone INR is within target (see Transition section) |
| Heparin / LMWH | Additive anticoagulation; also recurrence risk in HIT | Stop heparin/LMWH before starting argatroban; never co-administer |
| Direct oral anticoagulants (DOACs) | Additive anticoagulation; risk of major bleeding | Avoid concurrent use; allow appropriate washout based on DOAC half-life and renal function |
| Thrombolytics (alteplase, tenecteplase, reteplase, streptokinase) | Profoundly additive bleeding risk, especially intracranial | Concurrent use is not recommended outside of specialist indications; extreme caution required |
| Antiplatelet agents (aspirin, clopidogrel, ticagrelor, prasugrel) | Additive inhibition of haemostasis | Often co-prescribed during PCI with careful monitoring; assess individual bleeding risk |
| GP IIb/IIIa inhibitors (abciximab, tirofiban, eptifibatide) | Significant additive antithrombotic effect | Reduce argatroban dose and target lower aPTT range during PCI |
| NSAIDs | Platelet inhibition and mucosal injury | Avoid where possible; use paracetamol for analgesia instead |
| SSRIs / SNRIs (fluoxetine, paroxetine, venlafaxine) | Mild platelet dysfunction via serotonin depletion | No absolute contraindication; monitor for bleeding in high-risk patients |
| Dextran 40 / 70 | Platelet inhibition and factor VIII reduction | Avoid concurrent use |
Minor and Theoretical Interactions
| Drug / Class | Mechanism | Clinical Relevance |
|---|---|---|
| Erythromycin (potent CYP3A4/5 inhibitor) | Minor contribution to argatroban metabolism | Clinically non-significant interaction; no dose adjustment required |
| Paracetamol (acetaminophen) | No effect on argatroban pharmacokinetics | Safe analgesic of choice during argatroban therapy |
| Proton pump inhibitors (omeprazole, pantoprazole) | Theoretical reduction in GI bleeding risk via gastric acid suppression | Often co-prescribed prophylactically in ICU patients |
| Herbal supplements (ginkgo, garlic, fish oil, turmeric, ginger) | Theoretical antiplatelet activity | Discontinue before planned argatroban therapy where feasible |
Always inform the prescribing physician and treating team about every medication, dietary supplement, and over-the-counter product you are taking, including herbal remedies. This is particularly important in the ICU environment where multiple new medications may be started simultaneously. Pharmacists play a vital role in reviewing the full medication list for additive haemostatic effects during argatroban therapy.
Unlike warfarin, argatroban has few pharmacokinetic drug interactions. The main safety issue is pharmacodynamic additivity: any drug that impairs platelets or coagulation will increase bleeding risk when combined with argatroban. Because Novastan is used almost exclusively in intensive care and coronary intervention settings, these interactions are routinely assessed and managed by the treating team.
What Is the Correct Dosage of Novastan?
Novastan is administered only as a continuous intravenous infusion in a hospital setting under the supervision of a clinician experienced in the management of anticoagulation. The medication is supplied as a sterile concentrate for solution for infusion (100 mg/mL) that must be diluted before use, typically to a working concentration of 1 mg/mL using 0.9% sodium chloride, 5% dextrose, or lactated Ringer's solution. Dilution is performed under aseptic conditions; the diluted infusion bag should be mixed thoroughly and inspected for clarity before administration.
Adults with HIT
Standard Initial Dose (Normal Hepatic Function)
2 micrograms/kg/min as a continuous intravenous infusion. Check the aPTT 2 hours after initiation and after every dose change. Adjust the rate up or down (usually in increments of 0.5 micrograms/kg/min) to achieve a steady-state aPTT of 1.5-3 times the patient's baseline, not exceeding 100 seconds. The maximum dose is typically 10 micrograms/kg/min.
Moderate Hepatic Impairment (Child-Pugh B)
0.5 micrograms/kg/min initially, with careful titration. Argatroban clearance may be reduced by up to 75% in moderate hepatic impairment, and the half-life can increase from 40-50 minutes to 3-6 hours or longer. Frequent aPTT monitoring is essential.
Severe Hepatic Impairment (Child-Pugh C)
Use is generally contraindicated in Europe and carries a strong warning in the United States. If unavoidable, ultra-low starting doses (0.2 micrograms/kg/min or lower) and extremely close monitoring are required, ideally within a specialist haematology/critical care setting.
Critical Illness, Heart Failure, Post-Cardiac Surgery, Severe Anasarca
0.5-1.2 micrograms/kg/min initial infusion. These conditions impair hepatic perfusion and splanchnic blood flow, reducing argatroban clearance. Lower starting rates and more frequent aPTT monitoring reduce the risk of excessive anticoagulation.
Percutaneous Coronary Intervention (PCI) in Patients with or at Risk of HIT
During PCI, argatroban is administered as an intravenous bolus followed by a continuous infusion, with the goal of achieving a higher level of anticoagulation (typically targeting an activated clotting time [ACT] of 300-450 seconds) appropriate for the procedural vascular intervention:
- Bolus: 350 micrograms/kg given as a slow IV push over 3-5 minutes.
- Continuous infusion: 25 micrograms/kg/min, started immediately after the bolus.
- ACT check: Obtain an ACT 5-10 minutes after the bolus. If ACT <300 seconds, give an additional bolus of 150 micrograms/kg and increase the infusion to 30 micrograms/kg/min. If ACT >450 seconds, reduce the infusion to 15 micrograms/kg/min and recheck. Continue infusion for the duration of the procedure.
Continuous Renal Replacement Therapy (CRRT) and ECMO
Specialist centres use argatroban as an anticoagulant for extracorporeal circuits (CRRT, ECMO, cardiopulmonary bypass) in patients with HIT, although these uses are often off-label. Typical infusion rates are 0.5-2 micrograms/kg/min titrated to post-filter aPTT or anti-IIa targets. Local protocols vary and should be followed.
Children and Adolescents
Published paediatric experience suggests that argatroban clearance is reduced and half-life prolonged in critically ill children. Starting doses as low as 0.75 micrograms/kg/min (or lower in infants) have been proposed, with careful upward titration based on aPTT. Paediatric argatroban therapy should be managed by or in consultation with paediatric haematology specialists.
Elderly Patients
No specific dose adjustment is required based solely on age; however, elderly patients frequently have reduced hepatic perfusion, comorbidities, and polypharmacy that may necessitate lower starting doses and closer monitoring. The same principles applied to critically ill adults should be used.
Renal Impairment
No dose reduction is required for patients with renal impairment, including those receiving haemodialysis or continuous renal replacement therapy. This is because argatroban is eliminated primarily through hepatic metabolism rather than renal excretion, making it a preferred anticoagulant choice in patients with HIT and concomitant renal failure.
Missed Dose / Infusion Interruption
Because Novastan is administered as a continuous infusion in a monitored setting, missed doses are managed by the treating team. If the infusion is inadvertently interrupted (for example during line changes or patient transfer), the anticoagulant effect wanes rapidly due to the short half-life, and the infusion should be resumed at the previous rate with an aPTT rechecked 2 hours after resumption. A bolus is generally not required when resuming a continuous infusion.
Overdose
Overdose typically manifests as marked aPTT prolongation and bleeding. Stop the infusion immediately; the anticoagulant effect usually resolves within 2-4 hours in patients with normal hepatic function due to the short half-life. There is no specific antidote or reversal agent for argatroban. For significant bleeding, supportive measures include fluid resuscitation, blood product transfusion (packed red cells, fresh frozen plasma, platelets), and mechanical haemostasis. Haemodialysis and haemofiltration remove only a minor fraction of argatroban and are not reliable means of accelerating elimination. Prothrombin complex concentrate (PCC) and recombinant activated factor VII have been used anecdotally in severe bleeding, though evidence is limited.
What Are the Side Effects of Novastan?
Like all medicines, Novastan can cause side effects, although not everyone who receives it will experience them. Because argatroban is an anticoagulant, bleeding complications dominate its adverse event profile. The frequencies below are derived from pooled clinical trial data, post-marketing surveillance, and international product information from the EMA and FDA. Frequencies are expressed according to the standard Medical Dictionary for Regulatory Activities (MedDRA) conventions.
Very Common
May affect more than 1 in 10 people
- Minor bleeding (bruising, oozing from puncture sites, haematoma at catheter or cannula insertion sites)
- Decrease in haemoglobin and haematocrit (without overt bleeding)
Common
May affect up to 1 in 10 people
- Major bleeding: gastrointestinal haemorrhage, haematuria, haemoptysis, retroperitoneal haemorrhage (approximately 5-11% in HIT trials)
- Nausea and vomiting
- Fever (pyrexia)
- Hypotension (low blood pressure)
- Headache
- Diarrhoea
- Dyspnoea (shortness of breath)
- Abdominal pain
- Urinary tract infection
- Rash (non-allergic)
- Pain at infusion site
Uncommon
May affect up to 1 in 100 people
- Intracranial haemorrhage
- Haemopericardium
- Atrial or ventricular arrhythmias
- Cardiac arrest
- Allergic reactions including pruritus, urticaria, and rash
- Bronchospasm
- Abnormal liver function tests (raised ALT/AST, bilirubin)
- Coughing up blood (haemoptysis, moderate to severe)
- Hyperkalaemia
- Coagulopathy
Rare
May affect up to 1 in 1,000 people
- Anaphylactic reaction (including bronchospasm, angioedema, severe hypotension)
- Ventricular tachycardia
- Severe hepatic dysfunction (in addition to pre-existing disease)
- Sepsis associated with bleeding complications
Not Known
Frequency cannot be estimated from available data
- Delayed-onset HIT in patients switching from heparin (unrelated to argatroban)
- Paradoxical thrombosis despite therapeutic aPTT
- Skin necrosis at infusion site
- Injection-site reactions (induration, inflammation) with prolonged therapy
Understanding Bleeding Risk
Bleeding is the dominant safety concern with Novastan and all anticoagulants. In pivotal HIT clinical trials (ARG-911, ARG-915, ARG-915X), the incidence of major bleeding with argatroban was similar to or modestly higher than historical controls, with rates of approximately 6-11%, depending on the patient population, definitions of major bleeding, and concurrent antithrombotic use. Fatal bleeding occurred in approximately 1% of patients. Intracranial haemorrhage occurred in less than 0.5% of patients in clinical trials. Bleeding risk is higher in critically ill patients, those undergoing invasive procedures, and those receiving concurrent antiplatelet agents or thrombolytics.
The management of bleeding during argatroban therapy includes immediate discontinuation of the infusion, reversal of anticoagulation by time (the short half-life means effects resolve within hours), supportive care with blood products as indicated, and mechanical or surgical haemostasis where appropriate. Because argatroban has no specific antidote, the emphasis is on prevention through careful patient selection, avoidance of concurrent bleeding risk factors, and strict adherence to monitoring protocols.
Hypersensitivity and Allergic Reactions
Hypersensitivity reactions to argatroban are uncommon but have been reported. Reactions range from mild skin manifestations (pruritus, urticaria, rash) to severe anaphylaxis with bronchospasm, angioedema, and cardiovascular collapse. The formulation contains excipients (D-sorbitol and ethanol in the 100 mg/mL concentrate) that may rarely cause reactions in sensitive individuals. If a hypersensitivity reaction is suspected, the infusion should be stopped immediately and standard emergency management (adrenaline, corticosteroids, antihistamines, airway support) initiated.
Healthcare staff should alert the medical team immediately if any of the following occur during Novastan infusion: unexplained fall in haemoglobin, new confusion or focal neurological deficit, severe abdominal or back pain, significant drop in blood pressure, obvious external bleeding, black or tarry stools, visible blood in urine or sputum, severe injection-site pain, or signs of anaphylaxis (widespread rash, swelling of face or throat, difficulty breathing).
Reporting Adverse Reactions
If you or someone you care for experiences a side effect during Novastan therapy, inform the treating healthcare team. Healthcare professionals should report suspected adverse reactions through their national pharmacovigilance system (for example, Yellow Card in the UK, MedWatch in the US, or the EMA EudraVigilance system in the EU). Reporting suspected adverse reactions is critical for ongoing benefit-risk assessment of argatroban.
How Should You Store Novastan?
Because Novastan is administered exclusively in the hospital setting, storage is managed by hospital pharmacy services in accordance with the product label and local regulatory requirements. Patients and caregivers are not expected to store argatroban themselves. However, understanding the storage conditions reinforces the importance of medication quality and the precautions that healthcare professionals follow to ensure the drug remains safe and effective.
Storage of Unopened Vials
- Temperature: Store below 25 °C (77 °F). Do not refrigerate and do not freeze.
- Light protection: Keep the vial in the outer carton until use to protect from light.
- Expiry: Do not use after the expiry date printed on the label. The expiry date refers to the last day of the month indicated.
- Inspection before use: Immediately before preparation, the concentrate should be inspected visually. It should be a clear, colourless to pale yellow solution free of particulate matter. Do not use if the solution is cloudy, discoloured, or contains visible particles, or if the vial is damaged or has signs of tampering.
Storage of Diluted Solution
- The diluted infusion solution (typically 1 mg/mL) should ideally be prepared immediately before use.
- Once diluted in 0.9% sodium chloride, 5% dextrose, or lactated Ringer's solution, the solution is chemically and physically stable for up to 24 hours at 2-8 °C and up to 24 hours at 15-25 °C.
- From a microbiological perspective, once the solution has been prepared under non-controlled aseptic conditions, it should be used immediately. If not used immediately, in-use storage times and conditions before use are the responsibility of the user and should not normally exceed 24 hours at 2-8 °C.
- Protect the prepared infusion bag from direct sunlight during storage and administration.
- Do not use the prepared solution if it shows any signs of precipitation or colour change.
Disposal and Waste
Any unused medication or waste material should be disposed of in accordance with local regulations for cytotoxic and hazardous pharmaceutical waste, or at minimum as clinical waste via an approved pharmaceutical waste container. Do not dispose of argatroban via household waste or the domestic sewage system.
Like all small-molecule drugs administered parenterally, argatroban's chemical stability is essential to its safety and efficacy. Exposure to incompatible solutions, extreme temperatures, light, or oxidising agents can cause degradation and potential loss of anticoagulant activity. Hospital pharmacies follow strict aseptic compounding protocols (such as USP <797> in the US or EU GMP Annex 1) to safeguard these requirements.
What Does Novastan Contain?
Understanding the composition of a medication is important, particularly for patients with known intolerances to specific pharmaceutical excipients. The composition of Novastan (argatroban) varies slightly between regions and manufacturers, but the following information reflects the most common international formulations.
Active Ingredient
The active substance is argatroban (as argatroban monohydrate). The chemical name is (2R,4R)-1-[(2S)-5-[(aminoiminomethyl)amino]-1-oxo-2-[[(1,2,3,4-tetrahydro-3-methyl-8-quinolinyl)sulfonyl]amino]pentyl]-4-methyl-2-piperidinecarboxylic acid monohydrate. Argatroban is a synthetic small-molecule derivative of L-arginine with a molecular weight of approximately 526.7 g/mol (anhydrous). It is a reversible, highly selective inhibitor of thrombin.
Standard Presentations
Novastan (and other argatroban brands) is typically supplied as one of the following:
- Concentrate for solution for infusion, 100 mg/mL: Single-use 2.5 mL vials containing 250 mg of argatroban (as argatroban monohydrate). Must be diluted before administration.
- Solution for infusion, 1 mg/mL: Ready-to-use pre-diluted bags (typically 50 mL or 250 mL) available in some regions.
Excipients (Inactive Ingredients)
| Ingredient | Role | Notes |
|---|---|---|
| Argatroban (monohydrate) | Active substance (direct thrombin inhibitor) | 100 mg/mL concentration |
| D-Sorbitol | Solubiliser / tonicity agent | Improves aqueous solubility of argatroban |
| Dehydrated ethanol | Co-solvent | Small quantity; negligible clinical effect at therapeutic doses |
| Water for injections | Solvent | Qs to final volume |
| Hydrochloric acid / sodium hydroxide | pH adjustment | Used as needed to adjust pH (approximately 3.2-7.5 depending on formulation) |
Patients with Intolerances
Patients with known intolerance to sorbitol, fructose, or those with hereditary fructose intolerance (HFI) should inform their healthcare team before receiving argatroban formulations that contain D-sorbitol. The ethanol content, while small, may be relevant in neonates, pregnant or breastfeeding women, and patients with liver disease or epilepsy. Specific excipient content varies by manufacturer and region; consult the package insert for exact amounts.
Marketing Authorization Holders and Manufacturers
Argatroban is marketed internationally under several trade names. In addition to Novastan, other common brand names include Argatra (EU), Acova (US, discontinued), and Slovasc (various regions). Several generic argatroban formulations have been approved in the EU, US, and Japan. Marketing authorisation holders include Mitsubishi Tanabe Pharma (original developer), Mitsubishi Pharma Europe, Paion Deutschland, and various generic manufacturers. Current specific product information should be obtained from the product label or national summary of product characteristics (SmPC).
Frequently Asked Questions About Novastan
Novastan (argatroban) is a non-heparin intravenous anticoagulant that prevents and treats blood clots without the risk of triggering heparin-induced thrombocytopenia type II (HIT). HIT is a serious immune reaction where antibodies against heparin-platelet factor 4 (PF4) complexes activate platelets and cause paradoxical thrombosis despite a falling platelet count. When HIT is suspected or confirmed, heparin must be stopped immediately and replaced with a non-heparin anticoagulant. Novastan is a preferred choice because it acts directly on thrombin, does not cross-react with HIT antibodies, has a short half-life, and is eliminated by the liver rather than the kidneys, making it suitable even for patients with kidney failure.
Several direct thrombin inhibitors (DTIs) are available. Argatroban (Novastan) is a small synthetic molecule cleared by the liver with a short half-life of about 40-50 minutes. Bivalirudin (Angiomax, Angiox) is a synthetic peptide cleared primarily by proteolysis and partly by the kidneys; its half-life is around 25 minutes. Lepirudin (withdrawn from most markets) was a recombinant hirudin with renal elimination and a risk of anti-hirudin antibody formation. Dabigatran (Pradaxa) is an oral direct thrombin inhibitor used for atrial fibrillation and venous thromboembolism, not typically for acute HIT management. Argatroban's hepatic clearance makes it the preferred DTI for HIT patients with renal impairment, whereas bivalirudin may be preferred when hepatic function is severely impaired or during percutaneous coronary intervention.
The duration of argatroban therapy depends on the underlying clinical situation. For patients with HIT but without thrombosis, argatroban is typically continued until the platelet count has recovered (usually to >150 x 10^9/L) and the patient has been transitioned to an oral anticoagulant such as warfarin or a direct oral anticoagulant (DOAC). This is usually within 5-10 days. For patients with HIT-associated thrombosis, argatroban is continued alongside overlapping warfarin until a stable therapeutic INR is achieved, and then oral anticoagulation is continued for at least 3 months. During PCI, argatroban is given for the duration of the procedure plus a short post-procedural period.
Argatroban directly prolongs the prothrombin time (PT) and international normalized ratio (INR) because it inhibits thrombin, which is part of the final common pathway tested by these assays. This effect is over and above any additional effect of warfarin. If you are being transitioned from argatroban to warfarin, the INR will reflect the combined effect of both drugs and will appear higher than warfarin alone. Your healthcare team will use a standardised overlap protocol in which argatroban is discontinued once the combined INR exceeds about 4; the warfarin-alone INR is then rechecked 4-6 hours later to ensure it is within the therapeutic range of 2-3 before argatroban is stopped permanently.
Yes. One of the important advantages of argatroban is that it is eliminated almost entirely by the liver rather than the kidneys, so no dose reduction is required for renal impairment, including patients receiving intermittent haemodialysis, continuous renal replacement therapy (CRRT), or peritoneal dialysis. Argatroban is actually used as an anticoagulant within the extracorporeal circuit in selected CRRT protocols, particularly for patients with HIT who cannot receive heparin. Specialist centres use local protocols with either systemic or circuit-limited infusions, titrated to post-filter or systemic aPTT targets.
No specific antidote exists for argatroban. This is partly offset by its short half-life of 40-50 minutes in patients with normal hepatic function, meaning that simply stopping the infusion usually restores normal haemostasis within 2-4 hours. For patients with significant hepatic impairment, recovery may take longer. In cases of major bleeding, management is supportive: discontinue the infusion, support circulation with fluids and blood products (packed red cells, fresh frozen plasma, platelets as indicated), achieve mechanical haemostasis, and consider specialist input. Prothrombin complex concentrate (PCC) and recombinant activated factor VII have been used anecdotally but lack strong evidence. Haemodialysis removes only a small fraction of argatroban and is not a reliable means of reversal.
Experience in pregnancy is limited to case reports and small case series, primarily in pregnant patients with HIT in whom heparins are contraindicated. Argatroban does not bind to antithrombin and is a small molecule that may cross the placenta, but animal reproduction studies have not shown teratogenic effects. Danaparoid and fondaparinux have more pregnancy data than argatroban and are often preferred when available. Argatroban should be used during pregnancy only if clearly needed. It is not known whether argatroban enters human breast milk; the decision to breastfeed or discontinue argatroban should be individualised. Specialist obstetric and haematology advice is essential in this setting.
References
- European Medicines Agency (EMA). Argatra (argatroban) - Summary of Product Characteristics. Last updated 2025. Available at: EMA website.
- U.S. Food and Drug Administration (FDA). Argatroban Injection - Prescribing Information. Revised 2024.
- Cuker A, Arepally GM, Chong BH, et al. American Society of Hematology 2018 Guidelines for Management of Venous Thromboembolism: Heparin-Induced Thrombocytopenia. Blood Adv. 2018;2(22):3360-3392. doi:10.1182/bloodadvances.2018024489.
- Greinacher A. Heparin-Induced Thrombocytopenia. N Engl J Med. 2015;373(3):252-261. doi:10.1056/NEJMcp1411910.
- Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban Anticoagulant Therapy in Patients With Heparin-Induced Thrombocytopenia. Circulation. 2001;103(14):1838-1843. doi:10.1161/01.cir.103.14.1838.
- Lewis BE, Matthai WH, Cohen M, et al. Argatroban Anticoagulation During Percutaneous Coronary Intervention in Patients With Heparin-Induced Thrombocytopenia. Catheter Cardiovasc Interv. 2002;57(2):177-184. doi:10.1002/ccd.10276.
- Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and Prevention of Heparin-Induced Thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e495S-e530S. doi:10.1378/chest.11-2303.
- International Society on Thrombosis and Haemostasis (ISTH) Scientific and Standardization Committee. Guidance on the diagnosis and management of heparin-induced thrombocytopenia. J Thromb Haemost. 2023;21(7):1798-1820.
- Hursting MJ, Soffer J. Reducing Harm Associated with Anticoagulation: Practical Considerations of Argatroban Therapy in Heparin-Induced Thrombocytopenia. Drug Saf. 2009;32(3):203-218. doi:10.2165/00002018-200932030-00003.
- Swan SK, Hursting MJ. The Pharmacokinetics and Pharmacodynamics of Argatroban: Effects of Age, Gender, and Hepatic or Renal Dysfunction. Pharmacotherapy. 2000;20(3):318-329. doi:10.1592/phco.20.4.318.34881.
- British National Formulary (BNF). Argatroban. National Institute for Health and Care Excellence (NICE). 2025.
- Warkentin TE. How I Diagnose and Manage HIT. Hematology Am Soc Hematol Educ Program. 2022;2022(1):481-490. doi:10.1182/hematology.2022000352.
About Our Medical Team
All content on iMedic is created and reviewed by qualified medical professionals following international evidence-based guidelines. Our editorial process ensures accuracy, currency, and clinical relevance.
Medical Content Team
Specialists in haematology, critical care medicine, and clinical pharmacology with extensive experience in anticoagulation management, heparin-induced thrombocytopenia, and parenteral antithrombotic therapy.
Medical Review Board
Independent panel of board-certified physicians who verify all medical claims against current evidence and international guidelines (EMA, FDA, ASH, ISTH, BNF).
Editorial Standards
All content follows the GRADE evidence framework and is based on Level 1A evidence from systematic reviews and randomized controlled trials where available.
Independence
iMedic receives no pharmaceutical company funding or sponsorship. All content is editorially independent, ensuring unbiased medical information for patients and caregivers.